| Name | Abrezekimab |
|---|
| Description | Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-13 |
| References |
| No Any Chemical & Physical Properties |